Unibest

Pharmaceutical intermediates

Linperlisib Intermediates

1 pharmaceutical intermediate for Linperlisib. Indication: Follicular lymphoma.

提交项目All intermediates

About Linperlisib

Originator
Shanghai Haoyuan Pharmaceutical Co., Ltd
Indication
Follicular lymphoma
Approved Date
11/08/2022

Available intermediates

1 intermediate currently listed for Linperlisib. Request specifications, documentation or a quotation for any item below.

Linperlisib intermediates
Product NameCAS No.Molecular FormulaPhysical Properties
2-Methoxy-5-(4,4,5,5-tetramethyl-[1,3,2] dioxaborolan-2-yl)-pyridin-3-ylamine893440-50-1//

Other programs under L

(LCZ696)LanifibranorLapatinibLarotrectinibLasmiditanLazertinib MesylateLemborexantLenacapavir sodium

Building toward Linperlisib?

Tell us the step you need covered and the specification you are filing against. We will confirm supply, documentation and lead time.

提交项目 联系团队

我们能如何帮助您？

获取最新活动与法规动态洞察

直接发送到您的邮箱

在此获取行业洞察与 Unibest 动态

联系我们 →